Comparative Pharmacology
Head-to-head clinical analysis: AZASAN versus MYCOPHENOLATE MOFETIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZASAN versus MYCOPHENOLATE MOFETIL.
AZASAN vs MYCOPHENOLATE MOFETIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azathioprine is a purine analog that inhibits purine synthesis, thereby interfering with DNA and RNA synthesis. It is metabolized to 6-mercaptopurine, which inhibits T-cell activation and proliferation, leading to immunosuppression.
Mycophenolate mofetil is a prodrug that is rapidly hydrolyzed to mycophenolic acid (MPA), a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), which inhibits the de novo pathway of guanosine nucleotide synthesis. This inhibition preferentially blocks proliferation of T- and B-lymphocytes, as they are critically dependent on this pathway, thereby suppressing cell-mediated immune responses and antibody formation.
1-3 mg/kg/day orally once daily or divided twice daily; maximum dose 2.5 mg/kg/day for rheumatoid arthritis; usual dose 50-150 mg/day.
1 g orally twice daily; intravenous infusion 1 g over 2 hours twice daily for up to 14 days.
None Documented
None Documented
Clinical Note
moderateMycophenolate mofetil + Digitoxin
"Mycophenolate mofetil may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMycophenolate mofetil + Deslanoside
"Mycophenolate mofetil may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMycophenolate mofetil + Acetyldigitoxin
"Mycophenolate mofetil may decrease the cardiotoxic activities of Acetyldigitoxin."
Clinical Note
moderateMycophenolate mofetil + Ouabain
Terminal elimination half-life of azathioprine is approximately 4.5 hours (range 2–6 h), while its active metabolite 6-mercaptopurine has a half-life of 0.5–2 hours. Clinical context: Renal impairment prolongs half-life.
The terminal elimination half-life of mycophenolic acid (MPA) is approximately 8-16 hours in healthy volunteers and renal transplant patients. In patients with renal impairment, the half-life may be prolonged due to accumulation of MPAG. The half-life supports twice-daily dosing.
Renal: 88% as 6-mercaptopurine and metabolites; biliary: <10%
Mycophenolate mofetil is extensively metabolized to mycophenolic acid (MPA), which is primarily eliminated in urine as MPA glucuronide (MPAG). Approximately 87% of the dose is excreted in urine as MPAG, with less than 1% as unchanged MPA. Fecal excretion accounts for about 6% of the dose, mainly as MPAG. Biliary excretion contributes to enterohepatic recirculation of MPA, enhancing its exposure.
Category C
Category D/X
Immunosuppressant
Immunosuppressant
"Mycophenolate mofetil may decrease the cardiotoxic activities of Ouabain."